What was the primary driver of Cardinal Health's revenue growth in this quarter?

The primary driver of Cardinal Health's 16% operating revenue growth was increased sales volume across various customer segments, along with pharmaceutical price increases averaging approximately 5%. Acquisitions also contributed about 1% to the overall growth. The Pharmaceutical Distribution and Provider Services segment, in particular, showed strong sales to alternate site and chain pharmacies.

What are the 'special charges' mentioned in the report, and how did they impact earnings?

The special charges of $18.7 million in the current quarter and $12.3 million in the prior year's quarter were primarily related to merger integration costs (such as employee-related costs, distribution center consolidation, and other exit/integration costs) and other charges like manufacturing facility closures. These charges reduced earnings before the cumulative effect of accounting changes by $15.6 million in the current quarter and $7.6 million in the prior year's quarter.

What is the status of the proposed acquisition of Syncor International Corporation?

Cardinal Health is in the process of acquiring Syncor International Corporation in a stock-for-stock transaction valued at approximately $950 million. However, Syncor has been investigating improper payments made by its foreign subsidiaries, which were discovered during Cardinal Health's due diligence. This investigation has led to the postponement of Syncor's shareholder meeting to vote on the merger. Cardinal Health is continuing its due diligence and is assessing the situation; the completion of the transaction is not assured and is subject to various conditions.

How is the company managing its share repurchase program?

Cardinal Health's Board of Directors authorized a new $500 million share repurchase program on August 7, 2002, of which $219.8 million had been repurchased by September 30, 2002. An earlier $500 million program expired in August 2002, under which approximately $191.7 million worth of shares were repurchased during this quarter, bringing the total repurchased under that program to $500 million. These repurchases are for general corporate purposes.

CAH 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Cardinal Health Inc. reported strong financial results for the quarter ended September 30, 2002, with operating revenue growing 16% year-over-year to $11.4 billion. This growth was driven by all business segments, particularly Pharmaceutical Distribution and Provider Services, which benefited from increased sales volume and pharmaceutical price increases. Net earnings also saw a significant increase to $288.3 million, up from $176.3 million in the prior year's quarter, translating to a diluted EPS of $0.64 compared to $0.38. The company continued its strategic initiatives, including the integration of recent acquisitions and cost control efforts, which led to a reduction in selling, general, and administrative expenses as a percentage of revenue. While the company incurred special charges related to merger integration and facility closures, the core business operations demonstrated robust performance. Cardinal Health also provided an update on its proposed acquisition of Syncor International Corporation, noting that the transaction's completion remains subject to ongoing due diligence and satisfaction of closing conditions.

Key Highlights

1Operating revenue increased by 16% to $11.4 billion for the quarter ended September 30, 2002, compared to the prior year.
2Net earnings significantly increased to $288.3 million, a substantial rise from $176.3 million in the same period last year.
3Diluted earnings per share improved to $0.64, up from $0.38 in the prior year's quarter, excluding the cumulative effect of accounting changes.
4All four operating segments (Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services) contributed to revenue growth.
5The company repurchased approximately $219.8 million worth of common shares under a new $500 million authorization and $191.7 million under a prior $500 million authorization.
6Special charges totaling $18.7 million were incurred, primarily related to merger integration activities and manufacturing facility closures.
7The company is actively pursuing the acquisition of Syncor International Corporation, although completion is subject to ongoing due diligence and closing conditions.

CARDINAL HEALTH INC Quarterly Report for Q1 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions